Alzheimer’s Disease Drugs Market to Reach USD 14.3 Billion by 2032

Alzheimer’s Disease Drugs Market to Reach USD 14.3 Billion by 2032 as Early Diagnosis and Disease-Modifying Therapy Expand Treatment

The Global Alzheimer’s Disease Drugs Market was valued at approximately USD 3.9 billion in 2025 and is projected to reach about USD 14.3 billion by 2032, expanding at a CAGR of approximately 20.4% during 2026-2032.

The market is entering a period of rapid clinical and commercial change as treatment moves beyond traditional symptom management toward therapies designed to slow underlying disease progression. Earlier diagnosis, biomarker confirmation, anti-amyloid monoclonal antibodies and a large late-stage development pipeline are increasing the number of patients who may become candidates for disease-modifying therapy.

Alzheimer’s disease accounts for approximately 60%–70% of dementia cases globally. Around 57 million people were living with dementia worldwide in 2021, with nearly 10 million new cases occurring each year. In the United States alone, approximately 7.4 million adults aged 65 and older were living with clinical Alzheimer’s dementia in 2026.

The treatment opportunity is increasingly concentrated in early disease. The 2026 Alzheimer’s Association estimates that around 4.2 million Americans aged 65 and older may have mild cognitive impairment due to biological Alzheimer’s disease. This group is particularly important because currently approved disease-modifying therapies are intended primarily for patients with mild cognitive impairment or mild dementia associated with confirmed Alzheimer’s pathology.

Diagnosis remains a major barrier. A substantial share of patients with early cognitive impairment are not identified until disease progression is more advanced. Biomarker confirmation further narrows the addressable population because clinical Alzheimer’s symptoms do not always correspond with underlying amyloid pathology.

Blood-based biomarkers are beginning to improve this pathway. The FDA cleared the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio in May 2025, providing a less invasive option for identifying amyloid pathology in symptomatic adults. Roche subsequently received FDA clearance for the Elecsys pTau217 blood test in August 2026, expanding the potential use of blood biomarkers across primary and specialty care.

Disease-modifying therapies are now the highest-value segment of the market. Leqembi (lecanemab) received traditional FDA approval after its Phase III study involving 1,795 patients, while Kisunla (donanemab) was approved following a pivotal study involving 1,736 patients.

Lilly reported that donanemab slowed cognitive and functional decline by up to 35% in patients with less advanced pathology, while amyloid plaques declined by approximately 84% from baseline during the pivotal program. These therapies have shifted clinical evaluation toward measures such as CDR-SB, cognitive and functional decline, amyloid clearance and disease-stage progression.

Safety remains an important limitation. Amyloid-related imaging abnormalities, including ARIA-E and ARIA-H, require baseline and follow-up MRI monitoring. APOE ε4 status, cerebral microhemorrhages, anticoagulant use and other neurological conditions can further reduce treatment eligibility.

Administration is also changing. Traditional anti-amyloid antibodies depend heavily on infusion infrastructure, but the FDA approval of an at-home subcutaneous Leqembi initiation regimen in July 2026 introduced a more convenient treatment option and reduced dependence on repeated infusion-center visits.

Treatment economics remain significant. Intravenous Leqembi entered the U.S. market with an annual wholesale acquisition cost of approximately USD 26,500, while Kisunla treatment costs were reported at approximately USD 32,000 for 12 months. These figures exclude biomarker testing, MRI monitoring, specialist visits and administration.

The cost of treatment is being assessed against a much larger disease burden. U.S. health and long-term-care spending for people with Alzheimer’s and other dementias is projected to reach approximately USD 409 billion in 2026, excluding unpaid caregiving. The estimated lifetime cost of dementia care is approximately USD 405,262 per patient in 2024 dollars.

Pipeline activity remains strong. As of January 2026, approximately 158 drugs were being investigated across 192 active Alzheimer’s clinical trials, including 36 Phase III, 84 Phase II and 45 Phase I candidates. Around 73% of pipeline therapies are disease-targeting, with active programs focused on amyloid, tau, neuroinflammation, synaptic dysfunction, metabolic pathways and other mechanisms.

North America currently leads the global market due to early access to disease-modifying therapy, Medicare coverage, biomarker adoption and specialist infrastructure. Europe and Asia-Pacific are expected to gain importance as regulatory approvals, diagnostic capacity and reimbursement pathways expand.

The strongest commercial growth is expected to come from earlier patient identification, greater biomarker use, wider disease-modifying treatment penetration, more convenient administration and new therapies capable of treating broader patient groups than current anti-amyloid antibodies.